成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Icagen
Icagen
Icagen Icagen

美國Icagen 
主要研發用于治療疼痛和相關不適應癥狀的離子通道藥物。

Icagen is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads.
Ion channels are protein structures found in virtually every cell of the human body. Ion channels span the cell membrane and regulate the flow of ions, which are charged particles such as sodium, potassium, calcium and chloride, into and out of cells. There are currently numerous drugs that modulate ion channels and are marketed by third parties for multiple therapeutic indications.

Key elements of our ion channel technology include our cloning of over 300 human ion channel genes, which we believe represents substantially all of the human ion channel genome; expertise in developing high throughput screens for ion channel targets; ion channel focused chemistry libraries of over 250,000 compounds; proprietary computational chemistry methods; an extensive ion channel database, which integrates biological and chemical information about our targets and compounds; pharmacology and bioanalytic capabilities; and an extensive intellectual property portfolio consisting of United States patents and patent applications as well as numerous foreign counterparts. By integrating a number of scientific and drug development disciplines, we are able to efficiently discover and develop small molecule compounds that are more specific for the medically relevant ion channel, and therefore have a reduced likelihood of adverse side effects and clinical failure.

We pursue a target class approach to ion channel drug discovery. In this approach, we start with all potential ion channel targets and seek to identify applications to the treatment of various diseases. We believe that our approach provides for a more efficient drug discovery process, because our in-depth understanding of the targets and methods for finding small molecule modulators of these targets obviates the need to develop new research tools each time a new target is identified. Instead, we use our knowledge and skill to quickly find potential small molecule modulators of particular ion channel targets. We then use these small molecules to validate the particular target in a relevant animal model of disease. If a small molecule demonstrates activity in the animal model, it both validates the target and provides a starting point for further medicinal chemistry efforts.

Utilizing our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates that modulate ion channels.

Icagen is conducting clinical and preclinical studies in its core focus areas, which include the following:

 

Epilepsy and Pain
ICA-105665 is a novel opener of the KCNQ potassium ion channel which has

demonstrated a broad spectrum of activity in preclinical models of both

epilepsy and pain. In Phase I safety studies, the compound was shown to be

well tolerated in both healthy volunteers and in epilepsy patients. ICA-105665

was subsequently studied in patients with photosensitive epilepsy, with two of

the four patients tested in the 400mg dose cohort showing a positive

response. This study was subsequently extended to doses of 500mg and

600mg, but due to a serious adverse event in the 600mg dose cohort the

study was placed on clinical hold. In an extension to the multiple ascending

dose safety study in healthy volunteers, ICA-105665 continued to be well

tolerated at doses up to 600mg. The Company is currently discussing

potential next steps with its advisors and with the FDA, with analysis of the

complete data set from both studies ongoing.

Pain Control
Icagen has a broad research effort directed at novel ion channel targets for

pain control. In August, 2007, Icagen recently entered into a collaboration with

Pfizer for the discovery and development of novel pharmaceuticals directed

against three sodium channel targets. In addition, Icagen is pursuing

research directed at multiple ion channel targets in its pain control program.

Inflammatory Disorders
Icagen has identified several ion channel targets that are expressed at high

levels in some immune system cells and that may play an important role in

modulating the inflammatory response. Icagen has discovered compounds

that are active in vitro against some of these targets, leading to decreases in

calcium entry into immune system cells, decreases in immune system cell

proliferation, decreases in immune system cell migration into tissues and

other measures of inflammatory responses. Icagen has also demonstrated

effects of our compounds in animal models of inflammatory diseases

In addition to the areas noted above, Icagen is continuing to explore the human ion channel genome, for which it has completed the cloning of all human ion channel genes, to identify new therapeutic opportunities.

 

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 美女下部隐私(不遮挡) | 国产又爽又大又黄A片图片 五月婷av综合网色伊人苍井空 | 中文字幕乱在线伦视频乱在线伦视频 | 精品久久国产老人久久综合 | 亚洲卡一卡二新区永久时长 | 啊轻点灬大JI巴太粗熟妇 | 欧美精品一区久久 | 国产精品一二二区 | 最近中文国语字幕在线播放视频 | 国产精品日产欧美久久久久 | 亚洲精品永久在线观看 | 精品国产欧美日韩 | 中文字幕无线乱码人妻 | 黑人与岛国人妻熟女AⅤ | 精品国产AⅤ一区二区三区桃 | 国产成人AV网站网址 | 国产欧美一区二区精品婷婷 | 一性一交一口添一摸视频 | 三年片在线观看免费大全 | 亚洲精品黄色在线观看 | 午夜精品久久久久久久99老熟妇 | 肉丝肉足丝袜人妻在线无码 | 亚洲中文字幕在线乱码 | 成人爱做日本视频免费 | 精品久久久久一区二区三区 | 视频一区二区无码制服师生 | 精品国产午夜福利在线观看蜜月 | 国产精品人人爽人人做我的可爱 | 久久久久av | 亚洲天堂精品在线 | 美女扒开内裤无遮挡18禁 | 天天爱天天做天天爽歪歪 | 被按摩的人妻中文字幕 | 最近更新中文字幕第1 | 很色很黄很大爽的视频 | 久久国产专区 | 亚洲日韩国产精品乱-久 | 久久午夜福利无码1000合集 | 国产精品一区二区精品视频免费看 | 无码人妻精品一区二区蜜桃网站 | 亚洲人成色7777在线观看 |